Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy

PHASE2CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Allergic RhinitisRhinoconjunctivitis
Interventions
DRUG

placebo

SC injections of placebo on days 1, 7, 14, 28 and 56

DRUG

AllerT low dose

SC injections of AllerT 25-50 micrograms on days 1, 7, 14, 28 and 56

DRUG

AllerT full dose

SC injections of AllerT 50-100 micrograms on days 1, 7, 14, 28 and 56

Trial Locations (24)

1002

Paul Stradins Clinical University Hospital - Pulmonology Allergology, Riga

1003

Center of examination and treatment of allergic diseases, Riga

1005

Centre Hospitalier Universitaire Vaudois, Lausanne

2900

Allergiklinikken, Hellerup

4601

Viktorija Vevere private practice of Allergology, Rēzekne

5000

Klinisk Institute, Odense

8000

Lungemedicinsk Forskningsafdeling, Aarhus

10200

Antakalnio affiliation of the Vilnius City Allergy Center, Vilnius

20095

Alergotest, Lublin

22185

University hospital Skane, Lund

33100

Alergo-Med, Tarnów

41800

NZOZ Przychodnia Lekarska Hipokrates, Zabrze

50009

Kaunas Clinics University Hospital, Kaunas

51092

CHU de Reims, Reims

54203

Aler-med, Wroclaw

67000

Hopitaux Universitaires de Strasbourg, Strasbourg

70185

Orebro University Hospital, Örebro

72189

Lungavdelningen, Vastmanlands, Västerås

90153

SPZOZ Uniwersytecki Szpital Kliniczny - Allergology, Lodz

90553

Alergologii Centrum, Lodz

08431

Allergy Clinic JSC Perspektyvos, Vilnius

08661

Vilnius University Hospital, Vilnius

01157

Centrum Alergologii IRMED, Warsaw

50-368

Silesian Piasts University of Medicine in Wrocław, Wroclaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Anergis

INDUSTRY

NCT01720251 - Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy | Biotech Hunter | Biotech Hunter